Correlation Between Summit Therapeutics and Cheche Group

Can any of the company-specific risk be diversified away by investing in both Summit Therapeutics and Cheche Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Summit Therapeutics and Cheche Group into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Summit Therapeutics PLC and Cheche Group Class, you can compare the effects of market volatilities on Summit Therapeutics and Cheche Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Summit Therapeutics with a short position of Cheche Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of Summit Therapeutics and Cheche Group.

Diversification Opportunities for Summit Therapeutics and Cheche Group

-0.11

Correlation Coefficient

Summit Therapeutics  Cheche Group

Good diversification

The 3 months correlation between Summit and Cheche is -0.11. Overlapping area represents the amount of risk that can be diversified away by holding Summit Therapeutics PLC and Cheche Group Class in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cheche Group Class and Summit Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Summit Therapeutics PLC are associated (or correlated) with Cheche Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cheche Group Class has no effect on the direction of Summit Therapeutics i.e., Summit Therapeutics and Cheche Group go up and down completely randomly.

Pair Corralation between Summit Therapeutics and Cheche Group

Given the investment horizon of 90 days Summit Therapeutics is expected to generate 7.85 times less return on investment than Cheche Group. In addition to that, Summit Therapeutics is 1.26 times more volatile than Cheche Group Class. It trades about 0.0 of its total potential returns per unit of risk. Cheche Group Class is currently generating about 0.03 per unit of volatility. If you would invest  84.00  in Cheche Group Class on October 23, 2024 and sell it today you would earn a total of  3.00  from holding Cheche Group Class or generate 3.57% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Summit Therapeutics PLC  vs.  Cheche Group Class

Summit Therapeutics PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable primary indicators, Summit Therapeutics is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Cheche Group Class

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Cheche Group Class are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating fundamental indicators, Cheche Group may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Summit Therapeutics and Cheche Group

The main advantage of trading using opposite Summit Therapeutics and Cheche Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Summit Therapeutics position performs unexpectedly, Cheche Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cheche Group will offset losses from the drop in Cheche Group's long position.

The idea behind Summit Therapeutics PLC and Cheche Group Class pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.